NOVT
Overvalued by 68% based on the discounted cash flow analysis.
Market cap | $5.72 Billion |
---|---|
Enterprise Value | $5.98 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $2.02 |
Beta | 1.72 |
Outstanding Shares | 35,845,462 |
Avg 30 Day Volume | 133,326 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 78.52 |
---|---|
PEG | -435.64 |
Price to Sales | 6.65 |
Price to Book Ratio | 8.87 |
Enterprise Value to Revenue | 6.78 |
Enterprise Value to EBIT | 48.47 |
Enterprise Value to Net Income | 82 |
Total Debt to Enterprise | 0.06 |
Debt to Equity | 0.53 |
No data
No data
Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers ('OEMs') a competitive advantage. Novanta combines deep proprietary technology expertise and com...